ID   UM-SCC-22B
AC   CVCL_7732
SY   UM-SCC 22B; UMSCC-22B; UMSCC22B; UM-SCC22B; SCC22B; UMC-22b; UMC22b; UMC22B; UM-22B; University of Michigan-Squamous Cell Carcinoma-22B; 22B
DR   cancercelllines; CVCL_7732
DR   ChEMBL-Cells; CHEMBL3307244
DR   ChEMBL-Targets; CHEMBL612798
DR   Cosmic; 932291
DR   Cosmic; 948034
DR   Cosmic; 1130358
DR   Cosmic; 1483459
DR   Cosmic; 2131862
DR   Cosmic; 2513914
DR   Cosmic; 2602598
DR   IARC_TP53; 21637
DR   IARC_TP53; 25909
DR   Millipore; SCC077
DR   PubChem_Cell_line; CVCL_7732
DR   Wikidata; Q54990838
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=1958593;
RX   PubMed=3335022;
RX   PubMed=8679156;
RX   PubMed=9139877;
RX   PubMed=10956384;
RX   PubMed=15287027;
RX   PubMed=15495191;
RX   PubMed=16203773;
RX   PubMed=17312569;
RX   PubMed=18006756;
RX   PubMed=18487078;
RX   PubMed=19760794;
RX   PubMed=20145189;
RX   PubMed=20947470;
RX   PubMed=21868764;
RX   PubMed=23613873;
RX   PubMed=28196595;
RX   PubMed=29873307;
RX   PubMed=29156801;
RX   PubMed=31541927;
WW   https://tcpaportal.org/mclp/
CC   Problematic cell line: Partially contaminated. At least one lab used a stock contaminated by T24 (Cellosaurus=CVCL_0554) (PubMed=29873307).
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 34 +- 2 hours (PubMed=9139877).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1679Ter (c.5035G>T); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=15287027; PubMed=16203773; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=15287027; PubMed=16203773; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=31541927).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Millipore; PubMed=19760794; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 18
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 11,13
ST   FGA: 22,24
ST   Penta D: 13
ST   Penta E: 12,18
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,18
DI   NCIt; C4043; Hypopharyngeal squamous cell carcinoma
DI   ORDO; Orphanet_494547; Squamous cell carcinoma of the hypopharynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7731 ! UM-SCC-22A
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=1958593; DOI=10.1002/gcc.2870030406;
RA   Bradford C.R., Kimmel K.A., Van Dyke D.L., Worsham M.J., Tilley B.J.,
RA   Burk D., del Rosario F., Lutz S., Tooley R., Hayashida D.J.S.,
RA   Carey T.E.;
RT   "11p deletions and breakpoints in squamous cell carcinoma: association
RT   with altered reactivity with the UM-E7 antibody.";
RL   Genes Chromosomes Cancer 3:272-282(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=8679156; DOI=10.1007/BF00178278;
RA   Koldovsky P., Haas I., Bier H., Ganzer U.;
RT   "Immunohistochemical examination of 11 cell lines derived from human
RT   head and neck squamous cell carcinomas, their recurrences or
RT   metastases.";
RL   Eur. Arch. Otorhinolaryngol. 252:359-365(1995).
//
RX   PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J;
RA   Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A.,
RA   van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.;
RT   "Relationship between the parameters cellular differentiation,
RT   doubling time and platinum accumulation and cisplatin sensitivity in a
RT   panel of head and neck cancer cell lines.";
RL   Int. J. Cancer 71:410-415(1997).
//
RX   PubMed=10956384; DOI=10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V;
RA   Backus H.H.J., Pinedo H.M., Wouters D., Padron J.M., Molders N.,
RA   van der Wilt C.L., van Groeningen C.J., Jansen G., Peters G.J.;
RT   "Folate depletion increases sensitivity of solid tumor cell lines to
RT   5-fluorouracil and antifolates.";
RL   Int. J. Cancer 87:771-778(2000).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=15495191; DOI=10.1002/gcc.20119;
RA   Raschke S., Balz V., Efferth T., Schulz W.A., Florl A.R.;
RT   "Homozygous deletions of CDKN2A caused by alternative mechanisms in
RT   various human cancer cell lines.";
RL   Genes Chromosomes Cancer 42:58-67(2005).
//
RX   PubMed=16203773; DOI=10.1158/1078-0432.CCR-05-0378;
RA   Mandic R., Schamberger C.J., Muller J.F., Geyer M., Zhu L.,
RA   Carey T.E., Grenman R., Dunne A.A., Werner J.A.;
RT   "Reduced cisplatin sensitivity of head and neck squamous cell
RT   carcinoma cell lines correlates with mutations affecting the
RT   COOH-terminal nuclear localization signal of p53.";
RL   Clin. Cancer Res. 11:6845-6852(2005).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591;
RA   Friedman J., Nottingham L., Duggal P., Pernas F.G., Yan B., Yang X.-P.,
RA   Chen Z., Van Waes C.;
RT   "Deficient TP53 expression, function, and cisplatin sensitivity are
RT   restored by quinacrine in head and neck cancer.";
RL   Clin. Cancer Res. 13:6568-6578(2007).
//
RX   PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006;
RA   Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L.,
RA   Klussmann J.P., Hafner D., Schuler P., Friebe-Hoffmann U.,
RA   Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H.,
RA   Balz V.;
RT   "Alterations in the p53 pathway and their association with radio- and
RT   chemosensitivity in head and neck squamous cell carcinoma.";
RL   Oral Oncol. 44:1100-1109(2008).
//
RX   PubMed=19760794; DOI=10.1002/hed.21198;
RA   Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R.,
RA   Lyons R.H., Bradford C.R., Carey T.E.;
RT   "Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell
RT   lines.";
RL   Head Neck 32:417-426(2010).
//
RX   PubMed=20145189; DOI=10.1158/1940-6207.CAPR-09-0076;
RA   Chakravarti N., Kadara H., Yoon D.-J., Shay J.W., Myers J.N., Lotan D.,
RA   Sonenberg N., Lotan R.;
RT   "Differential inhibition of protein translation machinery by curcumin
RT   in normal, immortalized, and malignant oral epithelial cells.";
RL   Cancer Prev. Res. (Philadelphia) 3:331-338(2010).
//
RX   PubMed=20947470; DOI=10.1186/2047-783X-15-8-337;
RA   Schuler P.J., Trellakis S., Greve J., Bas M., Bergmann C., Bolke E.,
RA   Lehnerdt G., Mattheis S., Albers A.E., Brandau S., Lang S.,
RA   Whiteside T.L., Bier H., Hoffmann T.K.;
RT   "In vitro chemosensitivity of head and neck cancer cell lines.";
RL   Eur. J. Med. Res. 15:337-344(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29873307; DOI=10.1088/1361-6560/aacaba;
RA   Fru L.C., Adamson E.B., Campos D.D., Fain S.B., Jacques S.L.,
RA   van der Kogel A.J., Nickel K.P., Song C., Kimple R.J., Kissick M.W.;
RT   "Corrigendum: Potential role of the glycolytic oscillator in acute
RT   hypoxia in tumors (2015 Phys. Med. Biol. 60 9215).";
RL   Phys. Med. Biol. 63:139501-139501(2018).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//